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    Exocytosis of Lung Surfactants 
 
 A surfactant, by definition, is any molecule that is attracted to an interfacial region by 
nature of its structure (Notter 2000). Naturally then, the surface of the interior of the lungs has 
surfactants, termed lung surfactants, because of its interfacial properties (Notter 2000). On the 
surface of the lungs, there exists a constant interfacial surface tension between the liquid and gas 
phases. The lungs are the place where respiration and thus gas exchange occurs. More 
specifically, gas exchange occurs at the surface of the alveoli in the lungs (Moyes 2008). The 
alveoli are small hollow sacs that extend from the bronchiole of the lungs and in total there are 
millions of them within the lungs (Moyes 2008). Due to their size and unique shape, alveoli's 
primary function is to extend the surface area of the lungs in order to facilitate gas exchange with 
the external environment (Moyes 2008).  
 There are two types of cells that make up the alveoli. Type I alveolar cells make up most 
of the alveoli, have very thin walls, and are responsible for gas exchange (Moyes 2008). Within 
each alveolus, there exist fewer of the type II alveolar cells. These type II alveolar cells are 
responsible for secreting the components of the lung surfactant (Moyes 2008). The presence of 
the surfactant molecules at the interfacial region disrupts the cohesive forces between the water 
molecules in the alveoli fluid. This reduces surface tension at each alveolus (Moyes 2008). By 
reducing the surface tension at the alveolus, this increases the compliance of the lung. Lung 
compliance is a term used to describe how easily the lungs stretch during inhalation (Moyes 
2008). Reducing the surface tension thus allows the hollow sac of the alveoli to expand more 
readily, using less energy to overcome the surface tension barrier (Notter 2000). The magnitude 
by which surface tension is lowered by the presence of surfactants depends on a variety of 
factors. One example of an important factor is surfactant concentration; generally, the more 
surfactant present, the stronger its ability is to lower surface tension and increase lung 
compliancy (Notter 2000). Some other examples of factors which affect the magnitude by which 
surface tension can be lowered by surfactants are temperature changes, rate of surface film 
compression, and the type of surfactant molecules present in the surfactant film (Notter 2000). 
 Lung surfactant, sometimes referred to as pulmonary surfactant, consists of a mixture of 
85-90 percent phospholipids, 6-8 percent proteins, and 4-7 neutral lipids (Notter 2000). Of the 
phospholipid portion of surfactant, Dipalmitoylphosphatidylcholine (DPPC) is the major 
contributor and accounts for approximately 85 percent of the total phospholipid material (Notter 
2000). The phospholipid portion of surfactant material is secreted via specialized vesicles called 
lamellar bodies. On the other hand, the protein portion of the surfactant can be secreted 
independently of these lamellar bodies or in conjunction with lamellar bodies (Mason 1998).  
 Of the protein portion of the surfactant secretion, protein A is the major contributor and 
accounts for 50 percent of total protein content. This protein has actually been shown to inhibit 
secretion of lamellar bodies and thus it serves as a regulatory mechanism for the control of 
surfactant secretion (Dietl 2000). Smaller protein contributors include protein B, which accounts 
for 8 percent of surfactant protein, protein C, which accounts for 4 percent, and protein D, which 
accounts for around 1 percent (Notter 2000). Proteins B and C are small hydrophobic molecules 
which are localized within lamellar bodies and are thus co-secreted with lamellar bodies' 
contents (Deitl 2000). In contrast, proteins A and D are large hydrophilic molecules whose 
secretion is generally independent of lamellar bodies (Dietl 2000). 
 The excretion of lung surfactant from type II alveolar cells to the alveolar interfacial 
region is termed “exocytosis of lung surfactant” and regulation of this process is extremely 
important for maintaining normal and efficient respiratory function. The overall module that has 
been proposed for surfactant secretion involves multiple steps, many of which can be regulated 
individually by a variety of different factors. The first step in surfactant secretion is the synthesis 
and packaging of the surfactant molecules in the endoplasmic reticulum and the golgi body 
respectively (Weaver 2002). As discussed previously, most surfactant molecules are packaged 
into vesicles called lamellar bodies; however in contrast, others are packaged into multivesicular 
bodies which are thought to eventually fuse with lamellar bodies at some point before surfactant 
secretion (Dietl, 2000 and Weaver, 2002). Lamellar bodies (LB's) are specialized secretory 
granules that function in transporting the surfactant molecules from the area of synthesis 
outwards towards the apical plasma membrane of the cell where the contents will eventually be 
released via LB fusion (Mason 1998). These lamellar bodies are actually lysosome-related 
organelles containing lysosomal enzymes and an acidic pH as a result of an H+-ATP-ase (Weaver 
2003). Not only do lamellar bodies transport surfactant, but they also function in storing 
surfactant until the cell has been adequately stimulated. The second step in surfactant secretion 
thus is the stimulation of the type II alveolar cells. 
 Overall there are two main ways in which type II alveolar cells can be stimulated; by 
hyperventilation and by binding of agonists to receptor proteins (Mason 1998). There are several 
proposed mechanisms by which stimulation of exocytosis of lung surfactants via 
hyperventilation can occur. One likely mechanism that has been proposed is that physical stretch 
of the alveolar type II cells in the lung alveoli during tidal ventilation generates a transient 
increase in the cytoplasmic calcium concentrations which then stimulates secretion (Mason 
1998). Another possible mechanism is that perhaps surrounding lung cells, such as the type I 
alveolar cells are actually responsible for detecting the mechano-signal generated during tidal 
ventilation. Once these cells are stimulated by the hyperventilation, they may release a mediator, 
such as arachidonate metabolites, which can either travel via gap-junctions or diffuse through 
extracellular fluid. When the mediator binds to a receptor on the type II alveolar cell this then 
serves as the stimulation for secretion (Mason 1998). Other possible mechanisms include the 
reduction of PC02 during hyperventilation causing production of intracellular alkalosis or physical 
stretch of cells causing mechano-gated ion channels to open thereby causing membrane 
depolarization (Mason 1998). It has also been proven that even a deep inhalation can cause 
increased surfactant secretion via the same mechanisms as hyperventilation (Mason 1998). 
 Although agonists play an important role in stimulation of type II alveolar cells to release 
surfactants, it is thought that their effects are modest in comparison to the stimulation produced 
by hyperventilation (Mason 1998). An agonist is a molecule that binds to a receptor of a cell and 
triggers a response (Moyes 2008). Often times, agonists are drugs or other chemicals that mimic 
the shape and function of the true molecule that is responsible for stimulation of that specific 
receptor (Moyes 2008). In pulmonary type II cells, agonists are classified by two main types; 
those that cause a large impact on cell (increase of 4x normal secretion level) and those that have 
minimal impact on a cell (increase of <2x normal secretion level). Examples of agonists that 
cause a large impact on surfactant secretion rates are TPA, ATP, and other puregenic receptors 
(Mason, 1998 and Dietl, 2004). Examples of other agonists that cause a change in secretion rates 
include β2-mimetic drugs, gastrin releasing peptide, prostaglandin debris, vasopresin, 
endothelium-1, cholera toxin, and calcium ioniophase (Mason, 1998 and Dietl, 2000). It has been 
found that those agonists that have the largest effect on secretion generally act via a mechanism 
utilizing protein kinase C; however, details of this mechanism, while heavily researched, are still 
unclear (Mason 1998).  
 The complete mechanism by which many typical pharmaceutical agonists stimulate 
exocytosis of lung surfactant is a multi-step pathway. First, the agonist binds to the receptor on 
the cell surface. Second, this receptor-agonist complex then associates with heterotrimeric G-
proteins to activate phospholipase C. Phospholipase C then cleaves phosphatidylinositol 
bisphosphate to form diacylglycerol and IP3. Diacyglycerol then activates protein kinase C and 
meanwhile IP3 diffuses to the endoplasmic reticulum where it stimulates the release of calcium 
stores within this organelle. At this same time, channels on the extracellular matrix of the cell are 
stimulated to open up and more calcium is brought into the cell from the external environment. 
This series of events ultimately causes intracellular calcium concentrations to rise (Mason 1998). 
 Much research suggests that this rise in intracellular calcium levels is most likely the 
defining step in regulated exocytosis of lung surfactant in type II alveolar cells (Dietl 2000). This 
rise in Ca2+ levels is generally a key step no matter what the original mode of stimulation was: 
mechanosensors during hyperventilation and deep inhalations or chemoreceptors that respond to 
agonists. While scientists have suggested a few exceptions that involve cAMP acting as the 
primary second messenger rather than Ca2+ , these theories still remain unclear and difficult to 
prove (Dietl 2000). It is difficult to tell when cAMP acts, whether it is acting independently of 
Ca2+ or whether it acting in conjunction with Ca2+ (Dietl 2000) 
 Once Ca2+ levels have increased to a sufficient concentration, the pre-fusion phase of 
exocytosis begins. The pre-fusion phase of exocytosis is defined by three key steps; the 
stimulation of vesicles to move, the movement of vesicles through cytoplasm, and the docking of 
vesicles at docking proteins along the apical plasma membrane (Dietl 2000). When Ca2+ levels 
within the cell rise, this stimulates the LB's located throughout the cytoplasm to move towards 
the plasma membrane. The effect of Ca2+ stimulation on the relocation of LB's from inside of the 
cell to the plasma membrane of the cell is varied. A variety of factors influence the rate at which 
these LB's move towards the plasma membrane. For example, the spatial-temporal spreading of 
the Ca2+ signal and the size and location of the vesicle have effects on the rate at which the LB 
moves (Dietl 2000). The two most defining factors that are responsible for determining the 
movement of the vesicle are the duration of Ca2+ signal and the distance of the vesicle from the 
plasma membrane (Dietl 2000). Studies have shown that the further away a vesicle is from the 
Ca2+ signal or the shorter the Ca2+ signal is, the likelihood that the LB will move towards the 
plasma membrane and eventually fuse is reduced (Dietl 2000). The reason for this is because 
most of the barriers that the LB must pass before it reaches the cell membrane are Ca2+ -
dependent (Dietl, 2000 and Signh 2004). 
 In order for the LB's to move through the cell and out to the apical plasma membrane a 
series of interconnected events must occur, of which many are Ca2+ concentration dependent. 
Again, the first step is the stimulation of the vesicles to move from their resting location. This 
stimulation comes from the increased Ca2+ levels that develop within the cell once it has had the 
proper stimulation (Taran 2003). Then, in order for the vesicles to move through the cytosplasm, 
rearrangement of the cytoskeleton, that is acting as a barrier surrounding the vesicles, must occur 
(Taran 2003). This is an extremely important regulatory step in the process of exocytosis of lung 
surfactants and thus serves as another regulatory mechanism for controlling surfactant secretion.  
 The cytoskeleton has many important functions in regards to surfactant secretion. It 
serves as a barrier to regulate the release of secretory vesicles, a track for motor-mediated 
translocation of secretory vesicles, and a buffer surrounding the internal storage pool of secretory 
vesicles within the cell (Signh 2004). When the increased Ca2+ levels reach the F-actin strands 
surrounding the vesicles, the strands begin to decay which allows the vesicles to be released from 
storage. The exact reason why the F-actin strands begin to dissemble is not completely known. 
Some studies suggest that when Ca2+ levels reach a peak, this triggers exogenous annexin II to 
bind to specific segments of the F-actin strand, thereby disrupting its structure and causing it to 
partially disassemble (Signh 2004). Also, some studies have discussed the possibility of the 
existence of a second unique form of annexin II. This other form of annexin II is thought to act 
via a cAMP-dependent pathway rather than a Ca2+ -dependent pathway. This second form of 
annexin II is thought to already be bound to F-actin chains when the stimulus signal occurs 
(Signh 2004). When the alveolar cell is stimulated by some types of agonists, such as the β2-
mimetic drugs, this eventually results in a rise of cAMP and eventual activation of protein kinase 
A, which then phosphorylates the annexin II that is bound to the cytoskeleton (Signh 2004). 
Upon phosphorylation, the annexin II dissociates from the cytoskeleton, dismisses its F-actin 
binding activity, and therefore induces cytoskelton reorganization (Signh 2004).  
 Research also suggests one other possible mechanism that may explain the reorganization 
of the cytoskeleton during exocytosis of lung surfactants. This proposed mechanism involves 
Ca2+ -dependent actin-severing proteins. When intracellular Ca2+  levels rise within the cell, this 
activates the actin-severing proteins and as a result they bind to F-actin chains causing disruption 
of actin cross-linking (Signh 2004). Two examples of actin severing proteins are gelsolin and 
villin (Signh 2004). Research has proven also that at low Ca2+ concentrations, these two proteins 
actually assist with actin cross-linking thereby further supporting the conclusion that cytoskeltal 
reorganization during exocytosis of lung surfactants is highly Ca2+ dependent (Signh 2004). This 
research also supports the conclusion that as intracellular Ca2+ levels rise, this will eventually 
result in increased stimulation of surfactant secretion (Signh 2004 
 Studies suggest that with this reorganization of cytoskeleton, there is a change in shape of 
the alveolar type II cells (Dudek 2003). This change in shape suggests a contractile mechanism 
for the movement of LB's in which the LB's are propelled outwards towards the apical plasma 
membrane (Dietl 2000). This rearrangement of cytoskeleton thus directs the vesicles along 
certain pathways towards the membrane (Dudek 2001)). Once the vesicles reach and attach to 
the docking proteins on the apical plasma membrane, the LB fusion stage begins.  
 The LB itself has a lipid bilayer that surrounds the lumen. When this comes into contact 
with the phospholipid bilayer of the plasma membrane, the two membranes begin to fuse 
together (Haller 2001). The first step in LB fusion is the formation of a small fusion pore. This 
fusion pore is an aqueous channel between the vesicle lumen and the extracellular space (Haller 
2000). In the early stages for most fusions, the fusion pore is unstable and thus will generally 
fluctuate for several rounds between an open or closed state (Haller 2001). However, this is not 
the case for LB fusion within type II alveolar cells (Dietl 2000). Morphological and functional 
evidence suggest that LB fusion pores in type II alveolar cells are actually very stable and long 
lasting structures which allow for the slow and continual release of surfactants (Dietl 2000).  
 The difference in LB fusion in alveolar type II cells from other types of vesicle fusions is 
a result of the high lipid content within the LB (Dietl 2000). LB's of the alveolar type II cells 
carry large amount of phospholipids, such as DPPC, and when the aqueous fusion pore forms, 
water is not attracted to the hydrophobic contents of the LB (Dietl 2000). In other fusion pores, 
where the contents are hydrophilic, water rushes into the vesicle causing it to swell and rapidly 
expand the size of the fusion pore allowing for a quick release of the its contents (Dietl, 2000 and 
Haller, 2001). However, due to the hydrophobic nature of the LB contents, it suggests that 
another mechanism for fusion pore expansion must be directing this process. That mechanism is 
most likely Ca2+ dependent, as are most other regulatory mechanisms controlling the exocytosis 
of lung surfactants. Studies show that any increase in intracellular [Ca2+] causes acceleration of 
fusion pore expansion (Dietl 2000). Studies also show though that fusion pore expansion rate 
could also be a result of mechanical strain (Dietl 2000). It is not clear yet whether the mechanical 
strain acts directly on the fusion pore via cytoskeletal rearrangement of monomeric actin or if it 
acts indirectly via a resulting increase in [Ca2+] within the cell (Dietl 2000).  
 Once the LB fusion pore is formed, it will generally stay open and the LB will maintain 
its rigid shape until all of the contents have been expelled (Dietl 2000). However, sometimes a 
transient fusion results where the fusion pore closes up before all of the surfactant has been 
released. It is unclear whether the transient fusions result in decreased surfactant secretion or 
whether they result in simply a modification of surfactant secretion (Dietl 2000). It is possible 
that during this transient fusion, significant amounts of small and unbound LB constituents are 
released into the alveolar lining fluid (ALF) at this time (Dietl 2000). Also, there is the 
possibility that transient fusions may result in the backwards uptake and recycling of surfactant 
components (Dietl 2000). 
 Another unique event that sometimes occurs after LB fusion with the plasma membrane, 
is LB-LB fusion termed compound exocytosis (Dietl 2000). In this situation, a LB fuses with 
another LB and the contents of both vesicles are secreted via a single fusion pore. It is thought 
that this unique event is perhaps a method for focusing release of high levels of surfactant in a 
localized area where there are not enough docking proteins to support all of the LB's that have 
been stimulated to move towards the plasma membrane (Dietl 2000). Also, it has been suggested 
that compound exocytosis may actually be a mechanism that allows for slow and sustained 
release of surfactants to a specific area (Dietl 2000). 
 Over the time span of a few minutes to a half hour, LB's will continue fusing with the 
plasma membrane even after the [Ca2+ ] has begin to decline (Dietl 2000). Once the surfactant 
molecules reach the ALF, they quickly arrange themselves into a variety of structures including 
lamellar body-like particles (LBP's), tubular myelin (TM), a lipid-protein film, small 
vesicles(SV's) and others (Dietl, 2000 and Wright, 1991). These structures make up what is 
called the surfactant film (Wright, 1991). The specific arrangement of the surfactant film in the 
ALF greatly reduces surface tension in the lungs and helps to prevent alveolar collapse (Dietl 
2000). This surface film however is not a stagnant film and its contents are continually being 
reabsorbed, recycled, degraded, and rearranged as often as with each inhalation (Notter, 2000 
and Wright, 1991). For example, it is estimated that the pool of surfactant lipids present within 
the ALF has a turn-over rate of approximately 5-10 hours (Wright 1991). The surfactant film is 
constantly changing in order to meet the demands of the organism. For example, during exercise 
when the alveoli are processing an increased amount of air at an increased rate, the surfactant 
pool can increase by nearly 60 percent and then return back to normal levels when exercise is 
completed (Wright 1991).  
 As there are a variety of factors that stimulate rates of surfactant secretion, there are also 
as many factors stimulating rates of surfactant clearance. It is the precise balance between these 
two antagonistic processes that maintains the proper amount and the proper type of surfactant 
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